icon

Adverse events and oncotargeted kinase inhibitors / (Record no. 29788)

MARC details
000 -LEADER
fixed length control field 01467cam a22003257a 4500
001 - CONTROL NUMBER
control field 29788
003 - CONTROL NUMBER IDENTIFIER
control field MED
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250512124731.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 170807t20172017xx b 001 0 eng d
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER
LC control number 2017302047
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9780128094006 (hbk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 0128094001 (hbk.)
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)ocn959880103
040 ## - CATALOGING SOURCE
Original cataloging agency YDX
Language of cataloging eng
Transcribing agency YDX
Modifying agency BDX
-- OCLCQ
-- BTCTA
-- WSU
-- OCLCF
-- DLC
042 ## - AUTHENTICATION CODE
Authentication code lccopycat
050 00 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC271.P76
Item number T75 2017
082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 615.7/98
Edition number 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Tridente, G.,
Relator term author.
245 10 - TITLE STATEMENT
Title Adverse events and oncotargeted kinase inhibitors /
Statement of responsibility, etc. Giuseppe Tridente.
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. London :
Name of publisher, distributor, etc. Academic Press,
Date of publication, distribution, etc. ©2017.
300 ## - PHYSICAL DESCRIPTION
Extent xix, 715 p. ;
Dimensions 28 cm
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc. note Includes bibliographical references and index.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Introduction -- Kinases -- Kinase inhibitors -- Adverse events -- Imantinib -- Gefitinib -- Erlotinib -- Sorafenib -- Sunitinib -- Dasatinib -- Lapatinib -- Nilotinib -- Pazopanib -- Vandetanib -- Vemurafenib -- Crizotinib -- Ruxolitinib -- Axitinib -- Bosutinib -- Regorafenib -- Cabozantinib -- Ponatinib -- Dabrafenib -- Trametinib -- Afatinib -- Idelaisib -- Ibrutinib -- Overview -- Conclusion and perspectives.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Protein-tyrosine kinase
General subdivision Inhibitors.
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Protein-tyrosine kinase $x Inhibitors.
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Protein-tyrosine kinase
General subdivision Inhibitors.
Source of heading or term fast
Authority record control number or standard number (OCoLC)fst01079707
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
a 7
b cbc
c copycat
d 2
e ncip
f 20
g y-gencatlg
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Library of Congress Classification
Koha item type كتاب
Suppress in OPAC No
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Current library Date acquired Inventory number Total checkouts Full call number Date last seen Price effective from Koha item type Public note
    Library of Congress Classification     الطب الطب 05/12/2025 0006 1706   RC 271 05/12/2025 05/12/2025 كتاب مكتبة كلية طب الموصل